Helmholtz Gemeinschaft


Circulating omentin as a novel biomarker for colorectal cancer risk: Data from the EPIC - Potsdam cohort study

PDF (Manuscript (final draft)) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
[img] MS PowerPoint (Supplementary figures)

Item Type:Article
Title:Circulating omentin as a novel biomarker for colorectal cancer risk: Data from the EPIC - Potsdam cohort study
Creators Name:Aleksandrova, K. and di Giuseppe, R. and Isermann, B. and Biemann, R. and Schulze, M.B. and Wittenbecher, C. and Fritsche, A. and Lehmann, R. and Menzel, J. and Weikert, C. and Pischon, T. and Boeing, H.
Abstract:Omentin is a novel biomarker shown to exert metabolic, inflammatory and immune-related properties, and thereby could be implicated in the risk of colorectal cancer (CRC). So far, the association between omentin and CRC risk has not been evaluated in prospective cohort studies. We investigated the association between pre-diagnostic plasma omentin concentrations and risk of CRC in a case-cohort comprising 251 incident CRC cases diagnosed over a mean follow-up time of 10.4 years and 2,295 persons who remained free of cancer in the European Prospective Investigation into Cancer and Nutrition-Potsdam study. Hazard ratios as a measure of relative risk (RR) and 95% confidence intervals (CI-s) were computed using a Prentice modified Cox regression. In a model adjusted for established CRC risk factors, age, sex, education, dietary and lifestyle factors, body mass index (BMI) and waist circumference, higher omentin concentrations were associated with a higher CRC risk (RRcontinuously per doubling of omentin concentrations=1.98, 95%CI: 1.45-2.73). Additional adjustment for metabolic biomarkers, including glycated hemoglobin, high-density lipoprotein cholesterol and C-reactive protein, did not alter the results. In stratified analyses, the positive association between omentin and CRC risk was retained in participants with BMI< 30 (RRcontinuously per doubling of omentin concentrations=2.26; 95%CI: 1.57-3.27), whereas among participants with BMI{greater than or equal to} 30 no association was revealed (RRcontinuously per doubling of omentin concentrations =1.07; 95%CI: 0.63-1.83; Pinteraction= 0.005). These novel findings provide the first lines of evidence for an independent association between pre-diagnostic omentin concentrations and CRC risk and suggest a potential interaction with the adiposity state of the individual.
Keywords:Omentin, Colorectal Cancer, Novel Biomarker, Risk Assessment, Prospective Cohort
Source:Cancer Research
Publisher:American Association for Cancer Research
Page Range:3862-3871
Date:1 July 2016
Official Publication:https://doi.org/10.1158/0008-5472.CAN-15-3464
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library